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Abstract
Background: Expression of folylpoly-γ-glutamate synthetase (FPGS) gene is two- to three-fold higher in
B-precursor ALL (Bp- ALL) than in T-lineage ALL (T-ALL) and correlates with intracellular accumulation
of methotrexate (MTX) polyglutamates and lymphoblast sensitivity to MTX. In this report, we investigated
the molecular regulatory mechanisms directing FPGS gene expression in Bp-ALL and T-ALL cells.
Methods: To determine FPGS transcription rate in Bp-ALL and T-ALL we used nuclear run-on assays. 5'-
RACE was used to uncover potential regulatory regions involved in the lineage differences. We developed
a luciferase reporter gene assay to investigate FPGS promoter/enhancer activity. To further characterize
the FPGS proximal promoter, we determined the role of the putative transcription binding sites NFY and
E-box on FPGS expression using luciferase reporter gene assays with substitution mutants and EMSA.
Results: FPGS transcription initiation rate was 1.6-fold higher in NALM6 vs. CCRF-CEM cells indicating
that differences in transcription rate led to the observed lineage differences in FPGS expression between
Bp-ALL and T-ALL blasts. Two major transcripts encoding the mitochondrial/cytosolic and cytosolic
isoforms were detected in Bp-ALL (NALM6 and REH) whereas in T-ALL (CCRF-CEM) cells only the
mitochondrial/cytosolic transcript was detected. In all DNA fragments examined for promoter/enhancer
activity, we measured significantly lower luciferase activity in NALM6 vs. CCRF-CEM cells, suggesting the
need for additional yet unidentified regulatory elements in Bp-ALL. Finally, we determined that the putative
transcription factor binding site NFY, but not E-box, plays a role in FPGS transcription in both Bp- and T-
lineage.
Conclusion: We demonstrated that the minimal FPGS promoter region previously described in CCRF-
CEM is not sufficient to effectively drive FPGS transcription in NALM6 cells, suggesting that different
regulatory elements are required for FPGS gene expression in Bp-cells. Our data indicate that the control
of FPGS expression in human hematopoietic cells is complex and involves lineage-specific differences in
regulatory elements, transcription initiation rates, and mRNA processing. Understanding the lineage-
s p e c i f i c  m e c h a n i s m s  o f  F P G S  e x p r e s s i o n  s h o u l d  lead to improved therapeutic strategies aimed at
overcoming MTX resistance or inducing apoptosis in leukemic cells.
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Background
Folate antimetabolites play a central role as anticancer
agents. In mammalian tissues, intracellular folates and
antifolates exist as poly-γ-glutamates with typical chains
ranging from five to nine residues [1-3]. Polyglutamation
is catalyzed by folylpoly-γ-glutamate synthetase (FPGS)
and results in increased intracellular concentration and
cytoxicity of classical antifolates [4]. Furthermore, when
polyglutamated, some antifolates (e.g., raltitrexed, lome-
trexol) increase their Ki against targeted enzymes by over
100-fold [5,6]. In childhood acute lymphoblastic leuke-
mia (ALL) a strong correlation exists between FPGS
expression, intracellular methotrexate (MTX) polygluta-
mate accumulation and treatment outcome [4,7].
The FPGS gene is controlled by at least two mechanisms:
one tissue/lineage-specific and a second proliferation-
dependent [8-11]. FPGS activity is distributed to both
cytosolic and mitochondrial compartments of mamma-
lian cells. In humans, these two isoforms are encoded by
a single locus in chromosome region 9q (34.1–34.2) [12],
and differ by the use of two alternative translational start
sites within exon 1 [13]. Use of these alternative start sites
translates the FPGS protein with or without the addition
of a mitochondrial leader sequence. Alternative FPGS
exon 1 variants (exons 1, 1A, 1B, 1C, and 2A), all spliced
to exon 2, have been described [12,14]. We have demon-
strated no lineage-specific differences in the expression of
these alternative transcripts in human leukemia and nor-
mal tissues [15].
In mice, two promoters spaced by 10 kb were shown to
express distinct functional tissue-specific FPGS isoen-
zymes [16]. The upstream transcript (exon A1a) was
expressed only in few differentiated tissues such as liver,
whereas the downstream transcript (exon 1) was
expressed in dividing normal and neoplastic tissues. This
dual promoter mechanism directing expression of murine
isoenzymes is not conserved in humans. In contrast, the
human FPGS exon 1 transcript is present in both dividing
and differentiated tissues [14]. In human leukemia cells,
the enzyme translated from exon 1 transcript was reported
as the only catalytically active form. Transcription of the
human FPGS gene appears to be controlled by a TATA-less
promoter driven by a set of 8 concatameric Sp1 sites
spaced within a 150 bp region upstream of exon 1 [17].
Several additional transcription factors, including NFY (Y-
box) and E-box motifs have been identified within the
human minimal FPGS promoter region [13,17].
Our laboratory first demonstrated that constitutive levels
of FPGS mRNA, protein, and enzyme activity are two- to
three-fold higher in B-precursor (Bp) ALL cells compared
to T-lineage ALL [9,11]. We now report studies investigat-
ing the molecular mechanisms for this differential FPGS
gene expression. Our results demonstrate that FPGS tran-
scriptional start sites (+1) are the same in all hematopoi-
etic lineages studied. To analyze lineage differences in
FPGS promoter activity we used a FPGS promoter-luci-
ferase gene reporter assay. All DNA fragments examined
for promoter/enhancer activity exhibited higher levels of
luciferase activity in CCRF-CEM vs. NALM6 cells. Finally,
we determined the role of the putative NFY and E-box
transcription factor binding sites on FPGS gene transcrip-
tion using the same reporter gene assay with substitution
mutants and EMSA analysis.
Methods
Leukemia cell lines
The human leukemia cell lines CCRF-CEM (T-ALL) and
REH (Bp-ALL t(12;21)) were obtained from the American
Type Culture Collection. NALM6 (Bp-ALL) cell line was
obtained from DSMZ (Germany). RCH-ACV (Bp- ALL
t(1;19)) was kindly provided by Dr. Stephen Hunger
(UFL, Gainesville, FL). All cell lines were grown in RPMI
1640 (Sigma) supplemented with 10% FBS at 37°C and
5% CO2. Normal bone marrow (BM) was extracted from
normal volunteers. We obtained institutional review
board approval, and IRB approved informed consent was
obtained from normal volunteers prior to participation.
RNA isolation and real-time RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen Inc).
FPGS exons 14 and 15 were RT-PCR amplified [15] and
quantitated using pFPGS-cDNA, a pCR2.1-TOPO plasmid
containing the human FPGS cDNA gene (1926 bp; Table
1). Briefly, the 1926 pb FPGS cDNA gene was amplified by
PCR using primers 1exonF and 15exonR-c1934 (Table 1)
from total RNA reverse transcribed with primer 15exonR-
c2107 (5'-GGCCAGGCAGCGCACACAAT). Results were
normalized to β-actin mRNA expression. All real-time
PCR reactions (SYBR green) were performed using the
BIO-RAD iCycler iQ system (Bio-Rad) [18].
Nuclear run-on assay
Nuclear run-on assay was performed as described by Han-
son et al. [19]. One µg of FPGS and 18S RNA cDNAs were
blotted, UV cross-linked and hybridized with nascent
labeled RNA transcripts. After washing, membranes were
exposed to XAR-5 film (Kodak). Densitometric scan anal-
ysis was performed using the GelPro Analyzer program.
Results were normalized to the level of 18S RNA and sta-
tistic achieved using one-tailed, Student paired t-test
(GraphPad Prism, version 2.01). All data are expressed as
mean ± S.E.M.
5'-Rapid amplification of cDNA ends (RACE)
Amplification of the 5'-termini of FPGS mRNA was per-
formed using the 5'-RACE system Version 2.0 (Invitrogen
Corporation). Briefly, polyA+ RNA isolated from cellsBMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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Table 1: Oligonucleotides and plasmids used in this study.
PCR products/Plasmids Forward and Reverse primers/Description
1163 bp exon15-53F (5'-CGTTCTCCCCATGAACTTACA)
exon15-1215R (5'-AGGGTCTAGGCTGCAAGAAAG)
1374 bp intron0F-141 (5'-ACCCCAGCAGTGTGTGAAGAG)
intron1R-6537 (5'-CCCACCCCCAGATCAATACTC)
1926 bp 1exonF (5'-GGGGGCGCCGGGACTATGTCG)
15exonR-c1934 (5'-TCTCCCGGCCTCCCATCCCAA)
2158 bp 46714F (5'-AGAAGTTCTGGTGGGAAGGAA)
48871R (5'-CAGACCCTGGACTAGATGCTG)
2299 bp 48538F (5'-TAAGTGGGGGATGAGTCCAG)
50836R (5'-CCCAGATTCCAGCATCCTAA)
2628 bp 17595F (5'-GGCGCAGAGGCTAAGAATAAG)
20202R2 (5'-CCCCCAGCCTCCAGGATGTTC)
2881 bp exon15-53F (5'-CGTTCTCCCCATGAACTTACA)
exon15-2933R (5'-CCACACAGGAGTCAGGAATGT)
3588 bp F8256K (5'-GAGAGAGGTACCCCCGTGACTCCTGGTGGCTGC)
R11843K (5'-AATTCGGTACCCCTGGTCACCGGGTTCTCCTA)
4709 bp UA1F1979 (5'-CGCACACACCGCCAACTGTTC)
UA1R6667 (5'-CCTGGTCACCGGGTTCTCCTA)
4970 bp UAP-15639 (5'-GAGTGGCCCTTATGTACCGAC)
1R-20591 (5'-GGGCAACCGGCTCTTGAC)
ATGc QC20060F (5'-CGCAGGAGCCGAGCTCGGAGTACCAGGTAT)
QC20060R (5'-ATACCTGGTACTCCGAGCTCGGCTCCTGCG)
ATGm QC19934F (5'-GCGCCGGGACTAGTTCGCGGGCGCGG)
QC19934R (5'-CCGCGCCCGCGAACTAGTCCCGGCGC)
NFY-868 NFY-868F (5'-GACGCTGCGCTGAAAAGCTGGGGGCGGGGC)
NFY-868R (5'-GCCCCGCCCCCAGCTTTTCAGCGCAGCGTC)
Ebox-952 E47-952F (5'-GGGCGCGGAGCCATTCGCGCGCCGCTCTATTC)
E47-952R (5'GAATAGAGCGGCGCGCGAATGGCTCCGCGCCC)
139 bp (MSP)2 M19571F 5'-GTAGAGATTGAGGGTTGTTGATTC
M19709R 5'-CGAAACCAAATTTATAAATATACGCT
142 bp (MSP)2 U19571F 5'-GTAGAGATTGAGGGTTGTTGATTT
U19712R 5'-CCTCAAAACCAAATTTATAAATATCACT
pCR1163 1163 bp PCR fragment from NALM6 cloned into pCR2.1 TOPO
pCR1374 1374 bp PCR fragment from BM cloned into pCR2.1-TOPO
pCR2158 2158 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO
pCR2299 2299 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO
pCR2628 2628 bp PCR fragment from BAC RCPI-11 cloned into pCR2.1-TOPO
pCR2881 2881 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO
pCR4.7A1b 4709 bp PCR fragment from BM cloned in pCR2.1-TOPO
pCR4970 4970 bp PCR fragment from BAC RCPI-11 cloned into pCR2.1-TOPO
pFPGS-cDNA 1926 bp PCR from NALM6 cloned into pCR2.1-TOPO
pGL1163-2628 1163 bp Acc65I fragment PCR from pCR1163 cloned in pGL2628ATGm/
c
pGL1374 1374 bp HindIII PCR fragment from pCR1374 cloned into pGL3
pGL2158-2628 2158 bp Acc65I PCR fragment from pCR2158 cloned in pGL2628ATGm/
c
pGL2256 2316 bp HindIII fragment from pCR4.7-A1b cloned into pGL3
pGL2299-2628 2299 bp Acc65I PCR fragment from pCR2299 cloned in pGL2628ATGm/
c
pGL2628 2628 bp SacI-EcoRV fragment from pCR2628 cloned into pGL3
pGL2628-ATGc cytosolic ATG mutagenized to TCG (ATGc) in pGL2628
pGL2628-ATG mitochondrial ATG mutagenized to AGT (ATGm) in pGL2628
pGL2628-ATGm/c cytosolic ATG mutagenized to TCG (ATGc) in pGL2628-ATGm
pGL2881-2628 2881 bp Acc65I PCR fragment from pCR2881 cloned in pGL2628ATGm/
c
pGL3588-2628 3588 bp Acc65I PCR fragment from pCR4.7A1b in pGL2628ATGm/c
pGL4689 4708 bp EcoRV-BamHI fragment from pCR4970 cloned into pGL3
pGL868NFY-ATGm/c NFY-868 mutation in pGL2628-ATGm/c
pGL952NFY-ATGm/c Ebox-952 mutation in pGL2628-ATGm/c
1Nucleotides substituted are in bold italic. 2 MSP, Methyl-Specific PCR BM, normal human bone marrow genomic DNA.
To construct pGL1163-2628, pGL2158-2628, pGL2299-2628, pGL2881-2628, and pGL3588-2628, a sequence (5'-AATTCGGTACC) containing the 
Acc65I restriction site (underlined) was added to the 5'-end of the oligonucleotide primers used for the PCR amplification.BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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using the Oligotex Direct mRNA mini kit (Qiagen) were
reverse transcribed using the oligonucleotide Exon5R-F8
(5'-CTTGGTGAAGAGCTCAGGACTG), a gene-specific
primer in exon 5. The poly dC-tailed cDNA products were
amplified using a nested primer in exon 2, Exon2R-F4 (5'-
ACTCCGTGCCAGGTACAGTTCCATG), and the abridged
anchor primer. Primary PCR products were re-amplified
using an exon 2 upstream nested primer, 2exonR-2381
(5'-CAGGTAGCCGGCATTGGTCTG), and the abridged
universal amplification primer. 5'-RACE products were
separated on a 2.5% agarose gel, purified and cloned into
the pCR2.1-TOPO vector (Invitrogen). Identity of the 5'-
RACE products was determined by nucleotide sequence.
Construction of FPGS-luciferase reporter gene fusions
Regions of the FPGS gene promoter were generated by
PCR, cloned into pCR2.1-TOPO vector and sub-cloned
into pGL3-basic vector (Promega) or pGL2628-ATGm/c.
Plasmids and primers used in this study are listed in Table
1. The BAC clone RCPI-11 465E22 contains 188,098 bp of
human chromosome 9 including 104,600 bp upstream of
FPGS exon 1 (obtained from Dr. P.J. de Jong, Children's
Hospital Oakland). PCR conditions were optimized for
each of these fragments.
Nucleofection and luciferase reporter gene assays
The CCRF-CEM, NALM6 and REH cell lines were trans-
fected by nucleofection (Amaxa Biosystems) following
manufacturer's protocol. Briefly, 5 × 106 cells were resus-
pended in 100 µl of solution V® (CCRF-CEM and NALM6)
or R® (REH) and mixed with 2.5 µg of plasmid pGL1374
(FPGS promoter::luc) or equimolar concentration of
other FPGS promoter::luc plasmids, and 3 µg of pCMVβ.
Cells were incubated at 37°C/5% CO2 for 24 hrs, har-
vested, washed twice with cold PBS 1X and resuspended
in dual-light lysis buffer to yield cellular extracts. Luci-
ferase and β-galactosidase activities were assayed using the
dual-light reporter gene assay system (Tropix, Inc.). Trans-
fection efficiencies and cell viability were monitored by
flow cytometry. Cell viability was 70–75% and 78–85%
for CCRF-CEM and NALM6 cells, respectively. Statistical
tests were achieved using one-tailed, Student paired t-test
(GraphPad Prism, version 2.01).
Methylation-specific PCR analysis
Genomic DNA was isolated from CCRF-CEM and NALM6
cells using the DNeasy kit (Qiagen, Inc.) and treated with
sodium bisulfite to convert unmethylated cytosine to
uracil residues while 5-methylcytosines remain unaltered
(CpGenome DNA modification kit [Chemicon Interna-
tional]). Identification of CpG islands and design primer
sets were determined using the MethPrimer program [].
Chemically converted genomic DNA was PCR amplified
using specific primer sets for methylated and unmethyl-
ated forms (Table 1). Methyl-specific PCR (MSP) products
were resolved on a 3% agarose gel.
Site-directed mutagenesis
The QuikChange II XL Site-Directed Mutagenesis Kit
(Stratagene) was used to generate substitution mutants of
the human FPGS mitochondrial and cytosolic initiation
codons (ATG) from the pGL2628 plasmid using oligonu-
cleotides QC19934F/QC19934R and QC20060F/
QC20060R, respectively (Table 1). Similarly, FPGS puta-
tive NFY868 and E-box952 binding sites were muta-
genized using the plasmid pGL2628-ATGm/c plasmid
DNA template. Primers NFY-868F/NFY-868R and E47-
952F/E47-952R were used for the NFY and E-box muta-
genesis, respectively (Table 1). Mutations were confirmed
by nucleotide sequencing.
Nuclear extracts and electrophoretic mobility shift assay 
(EMSA)
Nuclear extracts were prepared from CCRF-CEM and
NALM6 cells using the NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Pierce, Biotechnology, Inc.). DNA-
protein interactions were carried out and detected using
the LightShift Chemiluminescent EMSA kit (Pierce, Bio-
technology, Inc.). Each EMSA reactions contained 25 nM
labeled FPGS -32/-14 (5'-CTGCGCTGATTGGCTGGGG)
oligonucleotides, 50 ng Poly (dI-dC) and 10 µg of nuclear
protein. When required, competitive unlabeled NFY DNA
oligomer, unlabeled Epstein-Barr nuclear antigen (EBNA)
DNA, and NFY antibody (CBF-A (C20) or CBF-B (H209)
(Santa Cruz, Biotechnology, Inc.)) were added to EMSA.
The DNA-protein complexes were resolved on non-dena-
turing 5% TBE polyacrylamide gels (Bio-Rad).
Results
FPGS transcription rate and mRNA transcription start sites 
in Bp- and T-ALL
To investigate whether differences in FPGS mRNA expres-
sion in Bp-ALL and T-ALL resulted from differences in
FPGS promoter transcription rate, we determined the fre-
quency of transcription initiation in CCRF-CEM and
NALM6 cells using nuclear run-on assays. As shown in
Figure 1A, ratio of FPGS/18S mRNA transcription rate was
1.64-fold higher in NALM6 (2.26 ± 0.768) vs. CCRF-CEM
(1.37 ± 0.416) cells (p < 0.05). These results are consistent
with the observed two- to three-fold higher levels of FPGS
mRNA, protein expression and activity in NALM6 vs.
CCRF-CEM [9,11,15].
To uncover potential regulatory regions involved in the
lineage differences in expression of the FPGS gene, we
localized the FPGS promoter in Bp-ALL vs. T-ALL cell lines
by mapping FPGS transcription initiation sites using 5'-
RACE. These experiments detected a long (~280 bp) and a
short (~180 bp) fragment, which were individually char-BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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acterized by nucleotide sequence analysis to encode mito-
chondrial/cytosolic and cytosolic FPGS, respectively. Long
fragments were detected in CCRF-CEM (T-ALL) whereas
both short and long fragments were amplified from
NALM6 and REH (Bp-ALL) (Figure 1B). Therefore, both
Bp-ALL and T-ALL cells use the same promoter to tran-
scribe FPGS mRNA but lineage differences in mRNA tran-
scripts exist.
FPGS transcription initiation rate and start sites in CCRF-CEM and NALM6 cells Figure 1
FPGS transcription initiation rate and start sites in CCRF-CEM and NALM6 cells. (A) Nuclear run-on assays. 
Intact nuclei were isolated from CCRF-CEM and NALM6 cells, and nascent RNA transcripts were labeled with [α-32P]UTP, 
purified, and hybridized to 1 µg of FPGS and 18S cDNAs blotted on nitrocellulose membrane. Integration densitometry values 
of FPGS and 18S signals were determined using the Gel-Pro program. Bars represent the mean of four independent experi-
ments ± S.E.M. Comparison of transcription rates were achieved using a Student's t-test (*, p < 0.05). (B) 5'-RACE products of 
FPGS mRNA from RCH (RCH-ACV), REH, NALM6, CEM (CCRF-CEM) and K562 cells are indicated. The lanes "CTRL" and 
"MW" represent negative control and the 100 bp DNA ladder, respectively. See Materials and Methods for details.BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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FPGS gene promoter activity in Bp- and T-ALL lineages
The human FPGS minimal promoter has been character-
ized in CCRF-CEM cells and encompassed a region start-
ing -43 bp from the main transcriptional start site to +150
bp of exon 1 [17] (see Figure 2). To further investigate the
mechanisms that control FPGS transcription in human
hematopoietic cells, we analyzed and compared DNA
fragments located upstream of exon A1b and in the 5'-
flanking region of exon 1 (encompassing the previously
described minimal promoter region) for promoter/
enhancer transcriptional activity in CCRF-CEM and
NALM6 cells. FPGS-luciferase transcriptional gene fusions
were constructed and assayed as described in Material and
Methods. Under our experimental conditions, transfec-
tion efficiencies were 38–50% and 42–50% in CCRF-CEM
and NALM6 cells, respectively. As shown in Figure 3, DNA
fragments located upstream of exon A1b (pGL2256 and
pGL3588-2628) yielded no promoter or enhancer activity
in both cell lines suggesting that the 5'-flanking region of
exon A1b exerts no regulatory activity on human FPGS
expression. The higher level of luciferase activity detected
in pGL3588-2628 vs. pGL2256 is likely the result of the
presence of the additional fragment of 2628 bp contained
in pGL3588-2628 that included the FPGS minimal pro-
moter region. When DNA fragments from the 5'-flanking
region of exon 1 (pGL1374, pGL2628-ATGm/c,
pGL4689) encompassing the described minimal pro-
moter were analyzed, we found 4- to 12-fold higher level
Schematic representation of the human FPGS gene and promoter region Figure 2
Schematic representation of the human FPGS gene and promoter region. FPGS exon A1b, exons 1 to 15, and the 
nucleotide sequence of the FPGS gene promoter region (accession # AL162586) are depicted. Putative transcription factor 
recognition motifs were identified using the MatInspector program from Genomatix (Release 7.3.1) [34]. Sp1 (GGGCGG; +5, 
-10, -15, -65, -72, -77, -82, -102, -147), NFY-box (CCAAT; -20 and -57), and E-box (CANNTG; +61) transcription factor bind-
ing sites are indicated. The protected DNase I footprint region, called H1 (+45 to +71) is shown underlined [17].BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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of luciferase/β-galactosidase activity in CCRF-CEM com-
pared to NALM6 cells (Figure 3). To validate our reporter
gene assay and rule out any technical differences in luci-
ferase activity in NALM6 vs. CCRF-CEM cells, we assayed
a CMV promoter-luciferase driven vector (pCMV-luc) and
found no significant differences in both cell lines (data
not shown). Therefore, these data indicate that DNA frag-
ments containing the previously described minimal pro-
moter region are not sufficient to effectively drive FPGS
transcription in Bp-ALL (NALM6) compared to T-ALL
(CCRF-CEM). Similar experiments with other Bp-ALL cell
lines such as RCH-ACV (t(1:19)) and REH (t(12;21)) were
performed and yielded same results (data not shown). To
exclude that differences in nucleotide sequence were
responsible for low promoter activity observed in Bp-ALL,
we PCR amplified and sequenced the 1374 bp fragment
containing the minimal promoter from normal bone
marrow (BM), CCRF-CEM and NALM6 cells. No differ-
ence in nucleotide sequence was detected.
The inability of the minimal promoter region to effi-
ciently drive FPGS transcription in NALM6 cells implied
that additional unidentified regulatory regions may be
required in Bp-ALL cells. To test this hypothesis we then
investigated the presence of enhancers or transcription
factors required for FPGS transcription in NALM6 vs.
CCRF-CEM cells, by analyzing the effect in cis of DNA
fragments located within the exons A1b-1 and in the 3'-
UTR of the FPGS gene on the FPGS-luc expression of
pGL2628-ATGm/c. As shown in Figure 3, plasmids
pGL2299-2628, pGL2158-2628, pGL1163-2628, and
pGL2881-2628 constructs yielded 1.8- to 4.2-fold lower
level of luciferase activity in NALM6 vs. CCRF-CEM cells.
Therefore, the regulatory elements required for FPGS gene
expression in Bp-ALL appear not to be localized within a
region encompassing 12 kb upstream of exon 1 nor
within the 3'-untranslated region.
Methylation status of the FPGS promoter in Bp- and T-
lineage
DNA methylation has been associated with transcrip-
tional inactivation and gene silencing [20,21]. Nucleotide
sequence analysis of the 1374 bp fragment (-791 to +582)
containing the FPGS minimal promoter predicted one
CpG island (54% GC content) at position -330 to +294.
We determined whether DNA methylation could contrib-
ute to the lineage-specific differences in FPGS expression
in ALL cell lines by methylation-specific PCR (MSP) anal-
ysis using bisulfite-treated DNA. Primers sets were
designed to anneal to unmethylated DNA (U) and meth-
ylated templates (M). As shown in Figure 4A, amplifica-
tion products (142 bp) were detected in both CCRF-CEM
FPGS promoter-luciferase constructs and activity in CCRF-CEM and NALM6 cells Figure 3
FPGS promoter-luciferase constructs and activity in CCRF-CEM and NALM6 cells. Genetic organization of the 
FPGS promoter-luciferase constructs is shown with their normalized luciferase/β-galactosidase activity in CCRF-CEM and 
NALM6 cells. Horizontal lines represent fragments cloned into pGL3 (luc) vector. Size of the fragments is indicated. Pointed 
boxes represent exons, and arrows direction of gene expression. Exponential cultures of CCRF-CEM and NALM6 cells (5 × 
106) were transfected by nucleofection with equimolar concentration of pGL1374/pCMVβ and other FPGS promoter::luc con-
structs as described in Materials and Methods. Luciferase activity (RLU; relative light units) was initially subtracted from the 
level of luciferase activity detected with pGL3 (empty vector) and normalized with respect to the level of β-galactosidase activ-
ity (RLU). Each experiment was performed at least two times in triplicate. Bars represent mean ± SD. See details in Materials 
and methods.BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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and NALM6 bisulfite-treated nuclear DNA with unmeth-
ylated primers (U) indicating a preferentially unmethyl-
ated CpG island in both cell lines. Control experiments
with untreated DNA or absence of template yielded no
products (data not shown). Quantitative analysis of cyto-
sine methylation was determined in both cell lines by
sequencing of the 142 bp unmethylated PCR amplicon.
This analysis revealed identical number of unmethylated
cytosines in both cell lines. Therefore, DNA methylation
of the CpG island region which contains the described
Methylation status and analysis of NFY and E-box transcription binding sites on FPGS expression Figure 4
Methylation status and analysis of NFY and E-box transcription binding sites on FPGS expression. (A) Genomic 
DNA from CCRF-CEM and NALM6 cells was treated with sodium bisulfite and DNA region of the FPGS gene promoter was 
PCR-amplified using primer sets specific to methylated (M) and unmethylated (U) forms (Table 1). Expected MSP products 
were M, 139 bp and U, 142 bp. L, 100 bp ladder molecular weight marker. (B) The putative NFY and E-box transcriptional 
binding sites were mutagenized as described in Materials and Methods. Wild type pGL2628-ATGm/c (grey bars) and mutated 
pGL868NFY-ATGm/c (black) and pGL952Ebox-ATGm/c (white) plasmids were transfected by nucleofection in CCRF-CEM 
and NALM6 cells. Level of luciferase activity (RLU) was initially subtracted from the level of luciferase activity detected with 
pGL3 (empty vector), standardized with respect to the level of β-galactosidase activity, and normalized to wild type pGL2628-
ATGm/c level. Each experiment was performed at least two times in triplicate. Data are expressed as mean ± S.E.M. (C) EMSA 
of biotinylated double stranded oligonucleotides containing the FPGS NFY binding site (region -32/-14) incubated with nuclear 
extracts prepared from CCRF-CEM (lanes 2–6) or NALM6 (lanes 7–10) cells. For competition experiments, 0.4 µM of unla-
beled NFY (lanes 3 and 8) or EBNA oligonucleotides (lane 6) were included in the reaction mixture. NFY antibody CBF-A 
(lanes 4 and 9) or CBF-B (lanes 5 and 10) were added to the reaction mixtures. Specific DNA-protein complexes C1 and C2, 
and the supershifted complex (SSC) are indicated. Lane 1 represents negative control with no nuclear extract.BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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FPGS minimal promoter does not play a role in the
observed lineage-specific differences in FPGS expression
in ALL cell lines.
Role of putative NFY-box and E-box binding sites on FPGS 
expression
To identify specific regulatory elements involved in FPGS
gene transcription, we analyzed the nucleotide sequence
of the minimal FPGS gene promoter for presence of
known transcription factor recognition motifs using the
MatInspector program (Genomatix, release 7.3.1). As
shown in Figure 2, two Sp1 (GGGCGG; -10, -15), one
reverse Sp1 (+5), one inverted NFY-box (CCAAT; -20),
and one E-box (CANNTG; +61) transcription factor bind-
ing sites were identified within the FPGS minimal pro-
moter (minP). We examined the role of putative NFY and
E-box DNA binding sites by generating mutants at each
site with substitutions reported to reduce or abolish gene
promoter activity [22,23]. Mutant constructs for NFY
(NFY-868; CCAAT → CTTTT) and E-box (Ebox-952; CAC-
CTG  → CATTCG) were co-transfected with pCMVβ in
both CCRF-CEM and NALM6 cells and assayed for luci-
ferase and β-galactosidase activities. As shown in Figure
4B, mutation in the NFY site (NFY-868) reduced the level
of FPGS transcription by 45% in NALM6 (p < 0.001) and
40% in CCRF-CEM cells (p < 0.005) when compared to
the wild type construct (pGL2628-ATGm/c). Normalized
luciferase activities were 1.9 × 10-2 ± 2.0 × 10-3 (pGL2628-
ATGm/c) and 1.0 × 10-2 ± 1.2 × 10-3 (pGL868NFY-ATGm/
c) in NALM6, and 2.4 × 10-1 ± 2.4 × 10-2 (pGL2628-
ATGm/c) and 1.5 × 10-1 ± 1.4 × 10-2 (pGL868NFY-ATGm/
c) in CCRF-CEM cells. These data suggest that the NFY
binding site is required to activate FPGS gene transcrip-
tion in lymphoid cells. In contrast, no significant differ-
ences were observed in either cell line with the mutant
Ebox-952 construct, suggesting a negligible role in FPGS
expression (Figure 4B). In NALM6 and CCRF-CEM cells,
the normalized level of luciferase activity was 1.6 × 10-2 ±
8.4 × 10-4 (pGL952Ebox-ATGm/c) and 2.2 × 10-1 ± 1.8 ×
10-2 (pGL952Ebox-ATGm/c), respectively.
To establish NFY protein interaction with the NFY-box
element (CCAAT) at position -20 upstream the FPGS gene
promoter, we performed electrophoretic mobility shift
assays (EMSAs) using an oligonucleotide probe contain-
ing FPGS gene sequence from -32 to -14. The sequences of
double-stranded biotinylated oligonucleotide probes and
competitors were incubated with nuclear extracts pre-
pared from CCRF-CEM or NALM6 cells. The EMSA
revealed the formation of two complexes with the NFY
oligonucleotide probe (Figure 4C, C1 and C2). To further
ascertain the specificity of binding, we demonstrated that
the formation of complexes C1 and C2 were inhibited by
excess amounts of unlabeled NFY oligonucleotides (Fig-
ure 4C, lanes 3 and 8) but not with unlabeled non-specific
Epstein-Barr nuclear antigen (EBNA) oligonucleotides
(Figure 4C, lane 6). To directly evaluate the proposed par-
ticipation of NFY in the shifted complexes, anti-NFY pep-
tide (CBF-A and CBF-B subunits) antibodies were
incubated with EMSA binding reactions before electro-
phoresis. Addition of anti NFY-A (CBF-A) antibody to
these reactions resulted in strongly retarded supershift
complex (SSC) (Figure 4C, lanes 4 and 9). In contrast,
addition of NFY-B (CBF-B) antibody abolished the forma-
tion of the complex C2 (Figure 4C, lanes 5 and 10) with-
out formation of a supershifted band. These data clearly
demonstrate that NFY transcription factor is present in the
complex that binds to the putative NFY binding site
(CCAAT) at position -20.
Discussion
Folate antimetabolites such as MTX are essential chemo-
therapeutic drugs in the treatment of children with acute
lymphoblastic leukemia (ALL). MTX is retained within the
cell by cellular metabolism catalyzed by the enzyme
FPGS. The human FPGS promoter has been previously
characterized using CCRF-CEM cells and it encompasses a
GC-rich region without a typical TATA sequence, usually a
characteristic of housekeeping genes and proto-onco-
genes. The minimal portion of the promoter required to
drive transcription in CCRF-CEM cells consists of a region
starting -43 to +150 of the main transcription start site
including part of exon 1 [17]. When 5'-flanking sequences
upstream of exon 1 were analyzed for promoter and/or
enhancer activity in Bp- vs. T-cells, we found significantly
lower luciferase activity in the Bp-ALL cell line NALM6
compared to the T-ALL cell line CCRF-CEM. These results
are opposite of what one would predict based on the
known lineage differences resulting in two- to three-fold
higher FPGS expression Bp- vs. T-ALL [9,11]. These low
levels of FPGS-luciferase activity observed with our con-
structs in NALM6 vs. CCRF-CEM cells, lead us to conclude
that the minimal promoter region is not sufficient to
effectively drive FPGS transcription in Bp-cells (NALM6).
Consequently, we hypothesize that additional regulatory
elements are required to drive FPGS expression in Bp-ALL.
Our analysis failed to demonstrate promoter and/or
enhancer activity in the immediate 5'-flanking region of
exon A1b, between exons A1b and 1, and in the 3'-UTR.
We propose that Bp-cell specific enhancer(s) are required
for FPGS gene expression in Bp-ALL cells and that distant
yet unidentified regulatory loci exist.
The human FPGS transcription start sites have been
mapped previously in human CCRF-CEM and HepG2
(hepatoma) cells and shown that FPGS transcription was
initiated from multiple start sites spread over 80 bp clus-
tered in two major regions differing by the presence of the
mitochondrial vs. cytosolic initiation codons [13,14,17].
The first transcription initiation site generates a long tran-BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
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script encoding both the mitochondrial and cytosolic iso-
forms of the enzyme, while the second start site generates
a shorter transcript encoding only the cytosolic protein.
Under our conditions, these two major transcripts were
detected only in Bp-ALL (NALM6 and REH) whereas in T-
ALL (CCRF-CEM) cells only the longer transcript was
detected. NALM6 cells which exhibited higher level of
FPGS mRNA expressed both transcripts, while in REH and
RCH-ACV which expressed intermediate levels of FPGS
mRNA the longer transcript (mitochondrial/cytosolic)
was either faint or absent, and in CCRF-CEM cells express-
ing the lowest level of FPGS mRNA the shorter transcript
(cytosolic) was absent. This finding is consistent with and
underscores regulatory differences in the expression of the
FPGS gene between Bp- and T-lineage ALL cells. It has also
led us to hypothesize that the additional expression of the
shorter transcript encoding for additional cytosolic pro-
tein in NALM6 cells could contribute to higher FPGS
mRNA expression leading to higher cytosolic protein
expression in these cells. Although speculative at this
time, this hypothesis which is currently being tested in our
laboratory is consistent with the higher protein and enzy-
matic activity observed in Bp-ALL vs. T-ALL. If confirmed,
the responsible regulatory elements could be used as tar-
gets for molecular or pharmacological interventions
aimed at increasing FPGS expression and overcome de
novo or acquired resistance in selected leukemic pheno-
types were low FPGS expression mediates unresponsive-
ness to MTX. An alternative, although unlikely
explanation is that failure from our 5'-RACE conditions to
amplify the short transcript or enriched amplification of
the longer form in CCRF-CEM cells resulted in these find-
ings.
The 5'-flanking region of the downstream FPGS promoter
contains eight forward/one reverse Sp1, two inverted NFY-
boxes, and one E-box putative binding sites (see Figure 2)
in which one NFY, one E-box, and three Sp1 binding sites
are present within the FPGS minimal promoter region
[17]. Functional activity of these Sp1 sites was previously
demonstrated [17]. Herein, we determined that the puta-
tive transcription factor binding site NFY, but not E-box,
plays a positive role in FPGS transcription in both Bp- and
T-lineages. Several studies have demonstrated that the
CCAAT box plays a role in gene transcription by binding
specific transcription factors such as C/EBP, NF-1, and
NFY [24-26]. EMSA experiments confirmed that the NFY
transcription factor is part of the complex that binds the
CCAAT sequence within the FPGS promoter. The NFY
transcription factor is involved in the regulation of many
TATA-less promoter genes such as RAG-1, [22,27], EPHX1
[25], and Gfi-1B [28]. Therefore, it is not unexpected that
NFY plays a role in the regulation of the TATA-less FPGS
promoter. In addition, it has been shown that NFY coop-
erates with many adjacent transcription factors such as
GATA-1 [28,29], C/EBPα [25], and Sp1 [30], through pro-
tein-protein interactions to mediate gene transcription.
Ongoing studies are investigating the interactions of NFY
and some of these proteins as regulators of FPGS gene
expression.
Within the FPGS promoter region we identified one CpG
island at position -330 to +294 encompassing Sp1 and
NFY sites. We found no role of promoter specific methyl-
ation in differential FPGS gene expression between CCRF-
CEM and NALM6 cells. Promoter regions with adjacent
CpG islands were found to initiate multiple transcripts
similar to those identified in FPGS transcription start sites
[31]. Therefore, nuclear factor(s) such as Sp1 that binds to
GC-rich motifs within the CpG island and NFY could
operate in conjunction to regulate human FPGS gene tran-
scription.
Conclusion
We demonstrated that the minimal FPGS promoter region
previously described in CCRF-CEM is not sufficient to
effectively drive FPGS transcription in NALM6 cells, sug-
gesting that different regulatory elements are required for
FPGS gene expression in Bp-cells. Our 5'-RACE analysis
showed that two major transcripts encoding the mito-
chondrial/cytosolic and cytosolic isoforms were expressed
in Bp-ALL (NALM6 and REH) whereas T-ALL (CCRF-
CEM) cells expressed only the mitochondrial/cytosolic
transcript. We determined that the putative transcription
factors binding site NFY, but not E-box, plays a role in
FPGS transcription in both Bp- and T-lineages. Taken
together, our data indicate that the control of FPGS
expression in human hematopoietic cells is complex and
involves lineage-specific differences in regulatory ele-
ments, transcription initiation rates, and mRNA process-
ing. Understanding the lineage-specific mechanisms of
FPGS expression should lead to improved therapeutic
strategies aimed at overcoming MTX resistance in leuke-
mic cells by upregulating FPGS and increasing accumula-
tion of MTX-PGs in those phenotypes with low FPGS
expression. Physiologically FPGS is also known to be
essential for eukaryotic cell survival although its targeted
inhibition as a novel anticancer strategy has been elusive
[32]. Further understanding of the genetic mechanisms
that control FPGS expression could also lead to the devel-
opment of novel molecular strategies capable of inducing
apoptosis in leukemic cells by selectively turning off FPGS
expression and could translate to better treatment out-
comes for children with high-risk or refractory ALL.
Competing interests
The author(s) declare that they have no competing inter-
ests.BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
Page 11 of 12
(page number not for citation purposes)
Authors' contributions
GJL conceived of the study, participated in its design, car-
ried out the molecular cloning, 5'-RACE, site-directed
mutagenesis, EMSA, methylation-specific PCR, transfec-
tion and luciferase/β-galactosidase assays, and drafted the
manuscript. GML participated in the primers design, site-
directed mutagenesis studies, EMSA, and statistical analy-
sis. TTHS participated in the nuclear run-on assays. JCB
conceived of the study, participated in its design and coor-
dination, and drafted the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We thank Dr. Dennis K. Watson for helpful discussions, Sanja Altman-
Hamamdzic for technical assistance with run-on assays, Drs. Jacqueline 
Kraveka and Tapas Sengupta for critical reading of the manuscript, and the 
Medical University South Carolina, Charleston, SC, USA, for their assist-
ance with DNA sequence analysis.
References
1. McGuire JJ, Bertino JR: Enzymatic synthesis and function of
folylpolyglutamates.  Mol Cell Biochem 1981, 38 Spec No(Pt
1):19-48.
2. McGuire JJ, Hsieh P, Coward JK, Bertino JR: Enzymatic synthesis
of folylpolyglutamates. Characterization of the reaction and
its products.  J Biol Chem 1980, 255(12):5776-5788.
3. Moran RG, Colman PD, Rosowsky A, Forsch RA, Chan KK: Struc-
tural features of 4-amino antifolates required for substrate
activity with mammalian folylpolyglutamate synthetase.  Mol
Pharmacol 1985, 27(1):156-166.
4. Synold TW, Willits EM, Barredo JC: Role of folylpolygutamate
synthetase (FPGS) in antifolate chemotherapy; a biochemi-
cal and clinical update.  Leuk Lymphoma 1996, 21(1-2):9-15.
5. Baldwin SW, Tse A, Gossett LS, Taylor EC, Rosowsky A, Shih C,
Moran RG: Structural features of 5,10-dideaza-5,6,7,8-tet-
rahydrofolate that determine inhibition of mammalian glyci-
namide ribonucleotide formyltransferase.  Biochemistry 1991,
30(7):1997-2006.
6. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH,
Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate
thymidylate synthase inhibitor that is a potent inhibitor of
L1210 tumor cell growth in vitro and in vivo: a new agent for
clinical study.  Cancer Res 1991, 51(20):5579-5586.
7. Rots MG, Willey JC, Jansen G, Van Zantwijk CH, Noordhuis P,
DeMuth JP, Kuiper E, Veerman AJ, Pieters R, Peters GJ: mRNA
expression levels of methotrexate resistance-related pro-
teins in childhood leukemia as determined by a standardized
competitive template-based RT-PCR method.  Leukemia 2000,
14(12):2166-2175.
8. Barredo J, Moran RG: Determinants of antifolate cytotoxicity:
folylpolyglutamate synthetase activity during cellular prolif-
eration and development.  Mol Pharmacol 1992, 42(4):687-694.
9. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans
WE: Differences in constitutive and post-methotrexate folyl-
polyglutamate synthetase activity in B-lineage and T-lineage
leukemia.  Blood 1994, 84(2):564-569.
10. Egan MG, Sirlin S, Rumberger BG, Garrow TA, Shane B, Sirotnak FM:
Rapid decline in folylpolyglutamate synthetase activity and
gene expression during maturation of HL-60 cells. Nature of
the effect, impact on folate compound polyglutamate pools,
and evidence for programmed down-regulation during mat-
uration.  J Biol Chem 1995, 270(10):5462-5468.
11. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo
JC, Pui CH, Relling MV, Evans WE: Differences in folylpolygluta-
mate synthetase and dihydrofolate reductase expression in
human B-lineage versus T-lineage leukemic lymphoblasts:
mechanisms for lineage differences in methotrexate poly-
glutamylation and cytotoxicity.  Mol Pharmacol 1997,
52(1):155-163.
12. Chen L, Qi H, Korenberg J, Garrow TA, Choi YJ, Shane B: Purifica-
tion and properties of human cytosolic folylpoly-gamma-
glutamate synthetase and organization, localization, and dif-
ferential splicing of its gene.  J Biol Chem 1996,
271(22):13077-13087.
13. Freemantle SJ, Taylor SM, Krystal G, Moran RG: Upstream organ-
ization of and multiple transcripts from the human folylpoly-
gamma-glutamate synthetase gene.  J Biol Chem 1995,
270(16):9579-9584.
14. Turner FB, Taylor SM, Moran RG: Expression patterns of the
multiple transcripts from the folylpolyglutamate synthetase
gene in human leukemias and normal differentiated tissues.
J Biol Chem 2000, 275(46):35960-35968.
15. Leclerc GJ, Barredo JC: Folylpoly-gamma-glutamate synthetase
gene mRNA splice variants and protein expression in pri-
mary human leukemia cells, cell lines, and normal human tis-
sues.  Clin Cancer Res 2001, 7(4):942-951.
16. Turner FB, Andreassi 2nd JL, Ferguson J, Titus S, Tse A, Taylor SM,
Moran RG: Tissue-specific expression of functional isoforms of
mouse folypoly-gamma-glutamae synthetase: a basis for tar-
geting folate antimetabolites.  Cancer Res 1999,
59(24):6074-6079.
17. Freemantle SJ, Moran RG: Transcription of the human folylpoly-
gamma-glutamate synthetase gene.  J Biol Chem 1997,
272(40):25373-25379.
18. Leclerc GJ, Leclerc GM, Barredo JC: Real-time RT-PCR analysis
of mRNA decay: half-life of Beta-actin mRNA in human
leukemia CCRF-CEM and Nalm-6 cell lines.  Cancer Cell Int
2002, 2(1):1.
19. Hanson RD, Connolly NL, Burnett D, Campbell EJ, Senior RM, Ley TJ:
Developmental regulation of the human cathepsin G gene in
myelomonocytic cells.  J Biol Chem 1990, 265(3):1524-1530.
20. Antequera F, Boyes J, Bird A: High levels of de novo methylation
and altered chromatin structure at CpG islands in cell lines.
Cell 1990, 62(3):503-514.
21. Razin A, Cedar H: DNA methylation and gene expression.
Microbiol Rev 1991, 55(3):451-458.
22. Brown ST, Miranda GA, Galic Z, Hartman IZ, Lyon CJ, Aguilera RJ:
Regulation of the RAG-1 promoter by the NF-Y transcrip-
tion factor.  J Immunol 1997, 158(11):5071-5074.
23. Nomura M, Bartsch S, Nawata H, Omura T, Morohashi K: An E box
element is required for the expression of the ad4bp gene, a
mammalian homologue of ftz-f1 gene, which is essential for
adrenal and gonadal development.  J Biol Chem 1995,
270(13):7453-7461.
24. Chodosh LA, Baldwin AS, Carthew RW, Sharp PA: Human
CCAAT-binding proteins have heterologous subunits.  Cell
1988, 53(1):11-24.
2 5 . Z h u  Q S ,  Q i a n  B ,  L e v y  D :  CCAAT/enhancer-binding protein
alpha (C/EBPalpha) activates transcription of the human
microsomal epoxide hydrolase gene (EPHX1) through the
interaction with DNA-bound NF-Y.  J Biol Chem 2004,
279(29):29902-29910.
26. Mantovani R: The molecular biology of the CCAAT-binding
factor NF-Y.  Gene 1999, 239(1):15-27.
27. Kurioka H, Kishi H, Isshiki H, Tagoh H, Mori K, Kitagawa T, Nagata
T, Dohi K, Muraguchi A: Isolation and characterization of a
TATA-less promoter for the human RAG-1 gene.  Mol Immu-
nol 1996, 33(13):1059-1066.
28. Huang DY, Kuo YY, Lai JS, Suzuki Y, Sugano S, Chang ZF: GATA-1
and NF-Y cooperate to mediate erythroid-specific transcrip-
tion of Gfi-1B gene.  Nucleic Acids Res 2004, 32(13):3935-3946.
29. Cassel DL, Subudhi SK, Surrey S, McKenzie SE: GATA and NF-Y
participate in transcriptional regulation of FcgammaRIIA in
megakaryocytic cells.  Blood Cells Mol Dis 2000, 26(6):587-597.
30. Liang F, Schaufele F, Gardner DG: Functional interaction of NF-
Y and Sp1 is required for type a natriuretic peptide receptor
gene transcription.  J Biol Chem 2001, 276(2):1516-1522.
31. Cross SH, Bird AP: CpG islands and genes.  Curr Opin Genet Dev
1995, 5(3):309-314.
32. Rosowsky A: Chemistry and biological activity of antifolates.
Prog Med Chem 1989, 26:1-252.
33. MethPrimer - Design Primers for Methylation PCRs   [http://
urogene.org/methprimer/index1.html]
34. Genomatix, MatInspector program   [http://www.genomatix.de/
cgi-bin/tools/tools.pl]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:132 http://www.biomedcentral.com/1471-2407/6/132
Page 12 of 12
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/132/pre
pub